riluzole has been researched along with 22q11.2 Deletion Syndrome in 2 studies
Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Riluzole is a potent anti-glutamatergic drug that reduces glutamatergic neurotransmission." | 5.51 | Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case. ( Tse, DHY; van Amelsvoort, T; Vingerhoets, C, 2019) |
| "Riluzole is a potent anti-glutamatergic drug that reduces glutamatergic neurotransmission." | 1.51 | Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case. ( Tse, DHY; van Amelsvoort, T; Vingerhoets, C, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Vingerhoets, C | 2 |
| Tse, DH | 1 |
| van Oudenaren, M | 1 |
| Hernaus, D | 1 |
| van Duin, E | 1 |
| Zinkstok, J | 1 |
| Ramaekers, JG | 1 |
| Jansen, JF | 1 |
| McAlonan, G | 1 |
| van Amelsvoort, T | 2 |
| Tse, DHY | 1 |
1 trial available for riluzole and 22q11.2 Deletion Syndrome
| Article | Year |
|---|---|
Glutamatergic and GABAergic reactivity and cognition in 22q11.2 deletion syndrome and healthy volunteers: A randomized double-blind 7-Tesla pharmacological MRS study.
Topics: Adult; Attention; Cognition; Corpus Striatum; Cross-Over Studies; DiGeorge Syndrome; Double-Blind Me | 2020 |
1 other study available for riluzole and 22q11.2 Deletion Syndrome
| Article | Year |
|---|---|
Riluzole effectively treats psychotic symptoms and improves cognition in 22q11.2 deletion syndrome: A clinical case.
Topics: Adult; Chromosomes, Human, Pair 22; DiGeorge Syndrome; Female; Glutamic Acid; Humans; Proline; Proli | 2019 |